Trastuzumab deruxtecan
Daiichi Sankyo,AstraZeneca,Leap Therapeutics
['tislelizumab', 'esophageal', 'dkn-01', 'gastroesophageal', 'distinguish']
#esmo22 | poster session 16 | saturday
dkn-01 and tislelizumab + chemotherapy as first-line (1l) investigational therapy in advanced gastroesophageal adenocarcinoma (gea): distinguish trial
presenter: sam klempner, md ( ) 
The official Twitter account for Mass General Cancer Center, a member of Mass General Brigham.